BioEye

Company Overview

Snapshot

Founded in January 2014 by Dovi Yellen, BioEye operates with 1-10 employees. The company has raised $200,000 across one funding round from one investor. In January 2014, BioEye secured pre-seed funding from the Office of the Chief Scientist.

Business overview

BioEye develops a mobile eye-tracking application designed to monitor cognitive states. Its core technology utilizes high-quality eye biomarkers such as eye movement, blink rate, and pupil size to provide continuous monitoring and early detection of cognitive decline. The application captures short videos of the eyes, extracts biomarkers, and sends them to a cloud-based big-data repository for analysis using machine-learning algorithms. BioEye operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics, serving both B2B and B2C markets globally, including healthcare providers and patients.

Company Intelligence Q&A

What is BioEye's primary focus?

BioEye focuses on monitoring cognitive states through a mobile eye-tracking application, providing early detection of cognitive decline and enabling effective intervention.

When was BioEye founded and by whom?

BioEye was founded in January 2014 by Dovi Yellen.

What is the core technology behind BioEye's platform?

BioEye's platform uses high-quality eye biomarkers, including eye movement, blink rate, and pupil size, extracted from short videos captured by a mobile application, and analyzed with machine-learning algorithms in the cloud.

Which markets does BioEye serve?

BioEye serves global markets, targeting both B2B and B2C customers, including healthcare providers and patients.

What was BioEye's last disclosed funding event?

In January 2014, BioEye secured pre-seed funding totaling $200,000 from the Office of the Chief Scientist.